Hepta, founded by former Illumina and Grail personnel, surfaced from stealth with transformer‑based AI that reads the cell‑free DNA epigenome to detect organ‑specific chronic disease signals and announced $6.7M in seed financing led by Felicis and Illumina Ventures. The company reported clinical performance detecting MASH with fibrosis (AUC ~0.86) and positions its assay as a liquid biopsy for chronic disease triage. Hepta said funding will expand datasets, scale the platform, and push toward regulatory milestones.